Single center, double blind, randomised, placebo-controlled study investigating Ampakine CX1739 in patients with mild-to-moderate obstructive sleep apnoea.

Trial Profile

Single center, double blind, randomised, placebo-controlled study investigating Ampakine CX1739 in patients with mild-to-moderate obstructive sleep apnoea.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2011

At a glance

  • Drugs CX 1739 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2011 Results have been reported in a Cortex Pharmaceuticals media release.
    • 03 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top